|
Jun 25
|
Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study
|
|
Jun 25
|
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
|
|
Jun 25
|
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty l...
|
|
Jun 24
|
Sector Update: Health Care Stocks Higher in Afternoon Trading
|
|
Jun 24
|
Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
|
|
Jun 23
|
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
|
|
Jun 18
|
Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth
|
|
Jun 18
|
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway
|
|
Jun 16
|
Hoth Therapeutics to Attend 2025 BIO International Convention
|
|
Jun 12
|
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
|
|
May 12
|
/C O R R E C T I O N -- Hoth Therapeutics, Inc./
|
|
Feb 10
|
Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic
|
|
Jul 24
|
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
|
|
Dec 27
|
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
|
|
Dec 5
|
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
|